A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma Interventions:   Drug: Pirtobrutinib;   Drug: Bendamustine;   Drug: Rituximab Sponsor:   Loxo Oncology, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials